Home breathing training shows promise for pompe patients
NCT ID NCT05431127
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether high-dose inspiratory muscle training (IMT) using a handheld device is safe and feasible for people with late-onset Pompe disease. 34 adults with stable Pompe disease did remote breathing exercises. Researchers measured changes in respiratory strength and patient-reported outcomes. The goal was to see if this home-based training could improve breathing and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Inspiratory muscle training using a Pr02 mobile device
- What this could lead to
- If successful, this could offer a safe, home-based breathing exercise program to help people with late-onset Pompe disease strengthen their respiratory muscles and improve daily life.
- What could go wrong
- This was a small, early feasibility study with only 34 participants and no control group. Results may not apply to everyone, and the training might not lead to meaningful long-term improvements.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LATE-ONSET POMPE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
Durham, North Carolina, 27705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an oral pill boost muscle strength in pompe disease?
- Pompe disease may raise risk of brain aneurysms, new study investigates
- Home infusions may help patients stick to treatment
- New drug DNL952 enters human testing for pompe disease
- New pompe disease drug moves to first human tests
- Major study aims to better measure muscular dystrophy progression